1. Pharmacokinetic overview of Ortho Evra™/Evra™
Larry S. Abrams, Ph.D., Donna Skee, M.S., Jaya Natarajan, Ph.D., Frankie A. Wong, M.S. 
Fertility and Sterility 
Volume 77, Pages 3-12 (February 2002)
DOI: /S (01)

2. FIGURE 1
(A), Mean serum concentration-versus-time profile of norelgestromin and ethinyl estradiol (EE) after a single 7-day patch application. (B), Mean serum concentration-versus-time profile of norelgestromin and EE after administration of the oral contraceptive Ortho-Cyclen®. Data for the patch and oral contraceptive are from two separate trials (data on file, Johnson & Johnson Pharmaceutical Research & Development, L.L.C.).
Abrams. Contraceptive patch pharmacokinetics. Fertil Steril 2002.
Fertility and Sterility  , 3-12DOI: ( /S (01) )

3. FIGURE 2
Mean serum concentration-versus-time profile of norelgestromin during the first patch application (0–168 hours, or days 0–7), the second patch application (168–408 hours, or days 7–17), and the terminal elimination phase (408–456 hours, or days 17–19). Dashed horizontal lines indicate the reference range. Vertical lines indicate the time of patch application or removal. Reprinted with permission (6).
Abrams. Contraceptive patch pharmacokinetics. Fertil Steril 2002.
Fertility and Sterility  , 3-12DOI: ( /S (01) )

4. FIGURE 3
Mean serum concentration-versus-time profile of ethinyl estradiol (EE) during the first patch application (0–168 hours, or days 0–7), the second patch application (168–408 hours, or days 7–17), and the terminal elimination phase (408–456 hours, or days 17–19). Dashed horizontal lines indicate the reference range. Vertical lines indicate the time of patch application or removal. Reprinted with permission (6).
Abrams. Contraceptive patch pharmacokinetics. Fertil Steril 2002.
Fertility and Sterility  , 3-12DOI: ( /S (01) )

5. FIGURE 4
Mean serum concentration-versus-time profile of norelgestromin after patch application on the buttock for three consecutive cycles. Dashed horizontal lines indicate the reference range. Css = steady-state concentrations. Reprinted with permission (13).
Abrams. Contraceptive patch pharmacokinetics. Fertil Steril 2002.
Fertility and Sterility  , 3-12DOI: ( /S (01) )

6. FIGURE 5
Mean serum concentration-versus-time profile of ethinyl estradiol (EE) after patch application on the buttock for three consecutive cycles. Dashed horizontal lines indicate the reference range. Reprinted with permission (13).
Abrams. Contraceptive patch pharmacokinetics. Fertil Steril 2002.
Fertility and Sterility  , 3-12DOI: ( /S (01) )

7. FIGURE 6
Mean serum concentration-versus-time profile of norelgestromin after successive applications of the contraceptive patch for 7 days at each of four anatomic sites. Dashed horizontal lines indicate the reference range. Reprinted with permission (7).
Abrams. Contraceptive patch pharmacokinetics. Fertil Steril 2002.
Fertility and Sterility  , 3-12DOI: ( /S (01) )

8. FIGURE 7
Mean serum concentration-versus-time profile of ethinyl estradiol (EE) after successive applications of the contraceptive patch for 7 days at each of four anatomic sites. Dashed horizontal lines indicate the reference range. Reprinted with permission (7).
Abrams. Contraceptive patch pharmacokinetics. Fertil Steril 2002.
Fertility and Sterility  , 3-12DOI: ( /S (01) )

9. FIGURE 8
Mean serum concentration-versus-time profile of norelgestromin under conditions of physical exertion and varying temperature and humidity. Dashed horizontal lines indicate the reference range. Reprinted with permission (15).
Abrams. Contraceptive patch pharmacokinetics. Fertil Steril 2002.
Fertility and Sterility  , 3-12DOI: ( /S (01) )

10. FIGURE 9
Mean serum concentration-versus time profile of ethinyl estradiol (EE) under conditions of physical exertion and varying temperature and humidity. Dashed horizontal lines indicate the reference range. Reprinted with permission (15).
Abrams. Contraceptive patch pharmacokinetics. Fertil Steril 2002.
Fertility and Sterility  , 3-12DOI: ( /S (01) )

11. FIGURE 10
Mean serum concentration-versus-time profile of norelgestromin after application of the contraceptive patch, with and without tetracycline administration (data on file, Johnson & Johnson Pharmaceutical Research & Development, L.L.C.).
Abrams. Contraceptive patch pharmacokinetics. Fertil Steril 2002.
Fertility and Sterility  , 3-12DOI: ( /S (01) )

12. FIGURE 11
Mean serum concentration-versus-time profile of ethinyl estradiol (EE) after application of the contraceptive patch, with and without tetracycline administration (data on file, Johnson & Johnson Pharmaceutical Research & Development, L.L.C.).
Abrams. Contraceptive patch pharmacokinetics. Fertil Steril 2002.
Fertility and Sterility  , 3-12DOI: ( /S (01) )